Regeneron: The Turnaround Is Gaining Steam

Group 1 - Brendan completed a Ph.D. in organic synthesis at Stanford University in 2009 and has a background in both pharmaceutical and biotech industries [1] - He worked for Merck from 2009 to 2013 and was involved in biotech startups such as Theravance and Aspira before joining Caltech [1] - Brendan is a co-founder of 1200 Pharma, which spun out of Caltech and received significant investment in the 8 figures [1] Group 2 - Brendan remains an avid investor, focusing on market trends, particularly in biotechnology stocks [1]